Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: A meta-analysis

BMC Gastroenterology

Volumn 13, Issue 1, 2013, Pages

  Xue, Tong Chun ^a   Xie, Xiao Ying ^a   Zhang, Lan ^a   Yin, Xin ^a   Zhang, Bo Heng ^a   Ren, Zheng Gang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Chemoembolization; Embolus; Hepatocellular carcinoma; Meta analysis; Portal vein

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DECOMPENSATED LIVER CIRRHOSIS; HUMAN; IATROGENIC DISEASE; LIVER CELL CARCINOMA; LIVER RESECTION; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PORTAL VEIN OBSTRUCTION; PORTAL VEIN THROMBOSIS; POSTEMBOLIZATION SYNDROME; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR THROMBUS;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASTIC CELLS, CIRCULATING; PORTAL VEIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84875856038     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-13-60     Document Type: Article

References (19)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010, 30:61-74. 10.1055/s-0030-1247133, 20175034.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390. 10.1056/NEJMoa0708857, 18650514.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34. 10.1016/S1470-2045(08)70285-7, 19095497.
5. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003, 37:429-442. 10.1053/jhep.2003.50047, 12540794.
6. Luo J, Guo RP, Lai ECH, Zhang YJ, Lau WY, Chen MS, Shi M. unresectable hepatocellular carcinoma with portal vein tumor thrombosis: A prospective comparative study. Ann Surg Oncol 2011, 18:413-420. 10.1245/s10434-010-1321-8, 20839057.
7. Niu ZJ, Ma YL, Kang P, Ou SQ, Meng ZB, Li ZK, Qi F, Zhao C. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Med Oncol 2012, 29:2992-2997. 10.1007/s12032-011-0145-0, 22200992.
8. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16. 10.1186/1745-6215-8-16, 1920534, 17555582.
9. Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer 1997, 11:2087-2094.
10. Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, Yoon JH, Lee HS, Kim YJ. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011, 258:627-634. 10.1148/radiol.10101058, 21273524.
11. Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol 2009, 24:806-814. 10.1111/j.1440-1746.2008.05728.x, 19207681.
12. Zhou Q, Wang Y, Zhou X, Peng B, Yang J, Liang L, Li J. Prognostic analysis for treatment modalities in hepatocellular carcinomas with portal vein tumor thrombi. Asian Pac J Cancer Prev 2011, 12:2847-2850.
13. Kim JH, Yoon HK, Kim SY, Kim KM, Ko GY, Gwon DI, Sung KB. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther 2009, 29:1291-1298. 10.1111/j.1365-2036.2009.04016.x, 19392861.
14. Peng ZW, Guo RP, Zhang YJ, Lin XJ, Chen MS, Lau WY. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer 2012, 118:4725-4736. 10.1002/cncr.26561, 22359112.
15. Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung JW, Chow P, Cheng AL. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology 2011, 81(Suppl 1):158-164.
16. Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, Tumino E, Ginanni B, Federici G, Cioni R. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011, 22:1545-1552. 10.1016/j.jvir.2011.07.002, 21849247.
17. Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Konigsberg R, Stauber R, Grunberger B, Muller C, Kolblinger C. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 2012, 263:590-599. 10.1148/radiol.12111550, 22438359.
18. Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, Buchler MW. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 2008, 8:349. 10.1186/1471-2407-8-349, 2630329, 19036146.
19. Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist 2012, 17:359-366. 10.1634/theoncologist.2011-0313, 3316921, 22334456.